Rifampin contraindications: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Rifampin }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RIFADIN (RIFAMPIN) CAPSULE RIFADIN IV (RIFA...")
 
No edit summary
 
Line 3: Line 3:
{{CMG}}; {{AE}} {{chetan}}
{{CMG}}; {{AE}} {{chetan}}


==Contraindications==
RIFADIN is contraindicated in patients with a history of hypersensitivity to rifampin or any of the components, or to any of the rifamycins. (See Warnings.)
Rifampin is contraindicated in patients who are also receiving [[ritonavir]]-boosted [[saquinavir]] due to an increased risk of severe hepatocellular toxicity. (See Precautions, Drug Interactions.)
Rifampin is contraindicated in patients who are also receiving [[atazanavir]], [[darunavir]], [[fosamprenavir]], [[saquinavir]], or [[tipranavir]] due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs, which may result in loss of antiviral efficacy and/or development of viral resistance.





Latest revision as of 23:13, 5 January 2014

Rifampin
FDA Package Insert (Rifadin®)
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Contraindications

RIFADIN is contraindicated in patients with a history of hypersensitivity to rifampin or any of the components, or to any of the rifamycins. (See Warnings.)

Rifampin is contraindicated in patients who are also receiving ritonavir-boosted saquinavir due to an increased risk of severe hepatocellular toxicity. (See Precautions, Drug Interactions.)

Rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs, which may result in loss of antiviral efficacy and/or development of viral resistance.



[1]


References

  1. "RIFADIN (RIFAMPIN) CAPSULE RIFADIN IV (RIFAMPIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [SANOFI-AVENTIS U.S. LLC]".

Adapted from the FDA Package Insert.